Tectonic Therapeutic, Inc. (TECX) stock
TECXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$21.96−0.01 (-0.05%)
Close on Nov 11, 2026Market cap $429.30MP/E –Yield 0.00%
Tectonic Therapeutic ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Tectonic Therapeutic's ebitda for the twelve months ending Sep 30, 2026 was -$95.32M. For fiscal 2025 it was -$82.66M. The highest annual figure on record is -$18.34M in fiscal 2017.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$82.66M | – |
| FY2024 | Dec 31, 2024 | -$56.37M | – |
| FY2023 | Dec 31, 2023 | -$43.17M | – |
| FY2022 | Dec 31, 2022 | -$103.99M | – |
| FY2021 | Dec 31, 2021 | -$117.44M | – |
| FY2020 | Dec 31, 2020 | -$119.02M | – |
| FY2019 | Dec 31, 2019 | -$74.96M | – |
| FY2018 | Dec 31, 2018 | -$45.86M | – |
| FY2017 | Dec 31, 2017 | -$18.34M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$23.21M | – |
| Q2 FY2026 | Jun 30, 2026 | -$23.93M | – |
| Q1 FY2026 | Mar 31, 2026 | -$27.00M | – |
| Q4 FY2025 | Dec 31, 2025 | -$21.18M | – |
| Q3 FY2025 | Sep 30, 2025 | -$21.55M | – |
| Q2 FY2025 | Jun 30, 2025 | -$21.99M | – |
| Q1 FY2025 | Mar 31, 2025 | -$17.94M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.48M | – |
| Q3 FY2024 | Sep 30, 2024 | -$19.21M | – |
| Q2 FY2024 | Jun 30, 2024 | -$11.09M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.59M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.00M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.74M | – |
| Q2 FY2023 | Jun 30, 2023 | -$10.34M | – |
| Q1 FY2023 | Mar 31, 2023 | -$24.89M | – |
| Q4 FY2022 | Dec 31, 2022 | -$24.92M | – |
| Q3 FY2022 | Sep 30, 2022 | -$22.65M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.42M | – |
| Q1 FY2022 | Mar 31, 2022 | -$29.02M | – |
| Q4 FY2021 | Dec 31, 2021 | -$27.53M | – |
| Q3 FY2021 | Sep 30, 2021 | -$32.25M | – |
| Q2 FY2021 | Jun 30, 2021 | -$31.08M | – |
| Q1 FY2021 | Mar 31, 2021 | -$26.59M | – |
| Q4 FY2020 | Dec 31, 2020 | -$27.76M | – |
| Q3 FY2020 | Sep 30, 2020 | -$36.42M | – |
| Q2 FY2020 | Jun 30, 2020 | -$28.56M | – |
| Q1 FY2020 | Mar 31, 2020 | -$26.31M | – |
| Q4 FY2019 | Dec 31, 2019 | -$23.19M | – |
| Q3 FY2019 | Sep 30, 2019 | -$17.85M | – |
| Q2 FY2019 | Jun 30, 2019 | -$16.41M | – |
| Q1 FY2019 | Mar 31, 2019 | -$17.51M | – |
| Q4 FY2018 | Dec 31, 2018 | -$16.49M | – |
| Q3 FY2018 | Sep 30, 2018 | -$12.10M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.50M | – |
| Q1 FY2018 | Mar 31, 2018 | -$7.77M | – |
| Q4 FY2017 | Dec 31, 2017 | -$7.41M | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.36M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.53M | – |
See a number that looks wrong?